Literature DB >> 10653449

Natural history of hepatitis C.

L B Seeff1.   

Abstract

It is now widely accepted that 85% or more of individuals with acute hepatitis C virus (HCV) infection progress to chronic hepatitis, and chronic hepatitis C is a known risk factor for cirrhosis and hepatocellular carcinoma (HCC). However, there has been much controversy about the inevitability of developing cirrhosis and HCC and the time frames in which they are likely to occur. Natural history studies have provided varying estimates of the risk of progression in chronic hepatitis C. Part of this variation may be a result of viral-specific, host, and/or environmental factors, but much of it undoubtedly is a result of the difficulties of doing natural history studies in this disease: acute onset is rarely identified, chronic infection is often asymptomatic, and the duration of disease is prolonged. Three types of studies--prospective, retrospective, and retrospective-prospective (nonconcurrent prospective)--have attempted to determine the clinical outcomes of chronic HCV infection and have provided widely varying estimates. The combined population data indicate that the disease progresses slowly over approximately 30 years, on average. Approximately 20% of infected individuals will progress to fibrosis and cirrhosis. Of these, approximately 20% will progress to HCC. The likelihood of progression appears to be independent of genotype or viral load but increases with alcohol intake, male sex, age over 40 years at infection, and coinfection with human immunodeficiency virus (HIV) or hepatitis B virus (HBV). Results of ongoing nonconcurrent studies are needed to determine disease progression in the third, fourth, and fifth decades of infection and to better define the factors that affect progression.

Entities:  

Mesh:

Year:  1999        PMID: 10653449     DOI: 10.1016/s0002-9343(99)00374-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  24 in total

Review 1.  Taking account of future technology in cost effectiveness analysis.

Authors:  Joshua A Salomon; Milton C Weinstein; Sue J Goldie
Journal:  BMJ       Date:  2004-09-25

2.  Prevalence of hepatitis C virus antibody among undergraduates in ogbomoso, southwestern Nigeria.

Authors:  Abiodun Christopher Jemilohun; Bolaji Oyetunde Oyelade; Sebastine Oseghae Oiwoh
Journal:  Afr J Infect Dis       Date:  2014

3.  Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes.

Authors:  Catherine A Lázaro; Ming Chang; Weiliang Tang; Jean Campbell; Daniel G Sullivan; David R Gretch; Lawrence Corey; Robert W Coombs; Nelson Fausto
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 4.  Acute hepatitis C virus infection: a chronic problem.

Authors:  Jason T Blackard; M Tarek Shata; Norah J Shire; Kenneth E Sherman
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

5.  Routine blood tests to predict liver fibrosis in chronic hepatitis C.

Authors:  Yung-Yu Hsieh; Shui-Yi Tung; Kamfai Lee; Cheng-Shyong Wu; Kuo-Liang Wei; Chien-Heng Shen; Te-Sheng Chang; Yi-Hsiung Lin
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

6.  Outcome of orthotopic liver transplantation in patients with hepatitis C.

Authors:  Seung W Paik; Henkie P Tan; Andrew S Klein; John K Boitnott; Paul J Thuluvath
Journal:  Dig Dis Sci       Date:  2002-02       Impact factor: 3.199

7.  High-level expression of the C-terminal hydrophobic region of HCV E2 protein ectodomain in E. coli.

Authors:  Jing Liu; Yuying Kong; Lixin Zhu; Yuan Wang; Guangdi Li
Journal:  Virus Genes       Date:  2002       Impact factor: 2.332

Review 8.  Hepatitis C treatment: current and future perspectives.

Authors:  Saira Munir; Sana Saleem; Muhammad Idrees; Aaliyah Tariq; Sadia Butt; Bisma Rauff; Abrar Hussain; Sadaf Badar; Mahrukh Naudhani; Zareen Fatima; Muhmmad Ali; Liaqat Ali; Madiha Akram; Mahwish Aftab; Bushra Khubaib; Zunaira Awan
Journal:  Virol J       Date:  2010-11-01       Impact factor: 4.099

9.  Proanthocyanidin from blueberry leaves suppresses expression of subgenomic hepatitis C virus RNA.

Authors:  Masahiko Takeshita; Yo-Ichi Ishida; Ena Akamatsu; Yusuke Ohmori; Masayuki Sudoh; Hirofumi Uto; Hirohito Tsubouchi; Hiroaki Kataoka
Journal:  J Biol Chem       Date:  2009-06-16       Impact factor: 5.157

10.  Dinucleotide analogues as novel inhibitors of RNA-dependent RNA polymerase of hepatitis C Virus.

Authors:  Weidong Zhong; Haoyun An; Dinesh Barawkar; Zhi Hong
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.